Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMALTHEA: AZD7798 in Moderate to Severe Crohn's Disease
jRCT2031240533Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing AZD7798 with Placebo (2 arms). Primary endpoint: CDAI remission at Week 12. Started Feb 2025; status: active, not recruiting.
02
Drugs
azd7798
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2031240533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240533.